15 June 2020>: Clinical Research
Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis
Sikai Nong BCD , Xinbin Pan BCD , Kaihua Chen EF , Ye Li CD , Xiaodong Zhu AFG*DOI: 10.12659/MSM.922244
Med Sci Monit 2020; 26:e922244
Table 3 Comparison of the different chemotherapy cycles between the 2 groups.
Chemotherapy | Cycle(N) | <6-cycle N(%) | ≥6-cycle N(%) | P-value |
---|---|---|---|---|
Palliative | 0.421 | |||
TPF | ≤4 | 19 (65.5%) | 16 (55.2%) | |
>4 | 10 (34.5%) | 13 (44.8%) | ||
Concurrent | 1.000 | |||
DDP | 0 | 20 (69.0%) | 21 (72.4%) | |
1 | 2 (6.9%) | 2 (6.9%) | ||
2 | 3 (10.3%) | 2 (6.9%) | ||
3 | 4 (13.8%) | 4 (13.8%) | ||
TPF – docetaxel, cisplatin and 5-fluorouracil; DDP – cisplatin. |